Free Trial
NASDAQ:VRDN

Viridian Therapeutics Q2 2025 Earnings Report

Viridian Therapeutics logo
$16.41 -0.12 (-0.73%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$16.43 +0.02 (+0.12%)
As of 08/8/2025 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viridian Therapeutics EPS Results

Actual EPS
-$1.00
Consensus EPS
-$1.00
Beat/Miss
Met Expectations
One Year Ago EPS
-$0.81

Viridian Therapeutics Revenue Results

Actual Revenue
$0.08 million
Expected Revenue
$0.05 million
Beat/Miss
Beat by +$28.00 thousand
YoY Revenue Growth
+4.20%

Viridian Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:00PM ET

Viridian Therapeutics Earnings Headlines

The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
See More Viridian Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Viridian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your email.

About Viridian Therapeutics

Viridian Therapeutics (NASDAQ:VRDN), a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

View Viridian Therapeutics Profile

More Earnings Resources from MarketBeat